$ARAT
Arax Holdings Corp

2023 Q1 Form 10-Q Financial Statement

#000175392623000287 Filed on March 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022 Q1
Revenue $226.9K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $212.3K $100.8K $23.62K
YoY Change 798.98% 793.09% 85.69%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $212.3K $100.8K $23.62K
YoY Change 798.98% 793.09% 85.69%
Operating Profit $14.55K -$23.62K
YoY Change -161.59%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.048M $0.00 $0.00
YoY Change
Pretax Income -$1.033M -$100.8K -$23.62K
YoY Change 4274.82% 793.09% 85.69%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$148.6K -$100.8K -$23.62K
YoY Change 529.18% 793.09% 85.69%
Net Earnings / Revenue -65.5%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.10 -$0.01 -$2.285K
COMMON SHARES
Basic Shares Outstanding 10.34M shares
Diluted Shares Outstanding 10.34M shares 10.34M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $27.89K
Short-Term Investments
Other Short-Term Assets $27.89K
YoY Change
Inventory
Prepaid Expenses
Receivables $226.9K
Other Receivables $0.00
Total Short-Term Assets $27.89K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $226.9K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $27.89K
Total Long-Term Assets $226.9K $0.00
Total Assets $254.8K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $36.67K $116.9K $16.02K
YoY Change 128.91% 725.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.142M $174.6K $49.63K
YoY Change 2201.65% 571.38% 290.17%
LONG-TERM LIABILITIES
Long-Term Debt $254.0K $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $254.0K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.142M $174.6K $49.63K
Total Long-Term Liabilities $254.0K $0.00 $0.00
Total Liabilities $1.396M $174.6K $49.63K
YoY Change 2713.49% 571.38% 290.17%
SHAREHOLDERS EQUITY
Retained Earnings -$1.920M -$879.0K -$754.0K
YoY Change 154.7% 20.35%
Common Stock $10.34K $10.34K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.142M -$174.6K -$49.63K
YoY Change
Total Liabilities & Shareholders Equity $254.8K
YoY Change

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022 Q1
OPERATING ACTIVITIES
Net Income -$148.6K -$100.8K -$23.62K
YoY Change 529.18% 793.09% 85.69%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$292.5K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $320.4K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -$292.5K 0.000
Cash From Investing Activities 0.000
Cash From Financing Activities $320.4K 0.000
Net Change In Cash $27.89K 0.000 $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$292.5K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001566243
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
CY2022Q4 us-gaap Assets Current
AssetsCurrent
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Revenues
Revenues
usd
CY2022Q1 arat Other Gain Or Loss
OtherGainOrLoss
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
usd
CY2022Q1 us-gaap Interest Paid
InterestPaid
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1920461 usd
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10335924 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10335924 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10335924 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10335924 shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-01-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
333-185928
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ARAX HOLDINGS CORP.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0376721
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
30 N Gould Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Sheridan
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
82801
CY2023Q1 dei City Area Code
CityAreaCode
850
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
254-1161
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12553807 shares
CY2023Q1 us-gaap Assets Current
AssetsCurrent
27887 usd
CY2023Q1 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
226886 usd
CY2023Q1 us-gaap Assets
Assets
254773 usd
CY2022Q4 us-gaap Assets
Assets
0 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36672 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
116869 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
684046 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1920461 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1058440 usd
CY2023Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
57756 usd
CY2023Q1 arat Gain Or Loss
GainOrLoss
-10561 usd
CY2022Q4 arat Gain Or Loss
GainOrLoss
57756 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1142307 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
174625 usd
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
254030 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
254030 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1396337 usd
CY2022Q4 us-gaap Liabilities
Liabilities
174625 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
10000 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
10000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10335924 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10335924 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10335924 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10335924 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
10335 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10335 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
758562 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-879006 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1141564 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-174625 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
254773 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2023Q1 us-gaap Revenues
Revenues
226886 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
212340 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23616 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
212340 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
23616 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
14546 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23616 usd
CY2023Q1 arat Other Gain Or Loss
OtherGainOrLoss
1047879 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1033333 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23616 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1033333 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-23616 usd
CY2023Q1 arat Net Income Loss Per Common Share Basic And Diluted
NetIncomeLossPerCommonShareBasicAndDiluted
-0.01
CY2022Q1 arat Net Income Loss Per Common Share Basic And Diluted
NetIncomeLossPerCommonShareBasicAndDiluted
-0.00
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10335924 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10335924 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-174625 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-148613 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1141564 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-26012 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23616 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-49628 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1033333 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23616 usd
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
226886 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-16346 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-80197 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7270 usd
CY2023Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
1058440 usd
CY2023Q1 arat Increase Decrease In Derivative Interest
IncreaseDecreaseInDerivativeInterest
10561 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-292537 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
66394 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
254030 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
320424 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
27887 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27887 usd
CY2022Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
33608 usd
CY2023Q1 arat Working Capital Deficit
WorkingCapitalDeficit
-1141564 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_zzHq3SS88gV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zFs1goz2yy34">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p>
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000000 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
33608 usd

Files In Submission

Name View Source Status
0001753926-23-000287-xbrl.zip Edgar Link pending
arat-20230131.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g083452_10q.htm Edgar Link pending
arat-20230131_cal.xml Edgar Link unprocessable
arat-20230131_def.xml Edgar Link unprocessable
arat-20230131_lab.xml Edgar Link unprocessable
arat-20230131_pre.xml Edgar Link unprocessable
0001753926-23-000287-index-headers.html Edgar Link pending
0001753926-23-000287-index.html Edgar Link pending
0001753926-23-000287.txt Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
g083452_ex31-1.htm Edgar Link pending
g083452_ex31-2.htm Edgar Link pending
g083452_ex32-1.htm Edgar Link pending
g083452_ex32-2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
g083452_10q_htm.xml Edgar Link completed